Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $4M Series B financing, bringing the total round to $29M. Participants include SR One, Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.